Palmitic Acid in the Sn-2 Position of Triacylglycerols and Postprandial Lipemia

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01710280

Enrollment

Registered

2012-10-19

Start date

2011-05-31

Completion date

2012-06-30

Last updated

2019-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Men, Raised Fasting Plasma Triacylglycerol Concentrations

Keywords

Lipemia, Vascular function, Blood pressure

Brief summary

The purpose of this study is to determine whether high-fat meals rich in palmitic acid in the sn-2 position decrease lipaemia in men aged 40-70 y with higher than optimal fasting triacylglycerol concentrations.

Interventions

DIETARY_SUPPLEMENTHigh-fat meal containing native palm olein

DIETARY_SUPPLEMENTHigh-fat meal containing interesterified palm olein

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

MALE

Age

40 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy males * Non-smokers * Aged 40-70 years * Fasting TAG concentrations ≥1.5 mmol/L.

Exclusion criteria

* Reported history of CVD (myocardial infarction, angina, venous thrombosis, stroke), impaired fasting glucose/uncontrolled type 2 diabetes (or fasting glucose ≥ 6.1 mmol/L), cancer, kidney, liver or bowel disease. * Presence of gastrointestinal disorder or use of drug, which is likely to alter gastrointestinal motility or nutrient absorption. * History of substance abuse or alcoholism (previous weekly alcohol intake \>60 units/men) * Current self-reported weekly alcohol intake exceeding 28 units * Allergy or intolerance to any component of test meals * Unwilling to restrict consumption of any source of fish oil for the length of the study * Weight change of \>3kg in preceding 2 months * Body Mass Index \<20 and \>35 kg/m2 * Fasting blood cholesterol \> 7.8 mmol/L * Current cigarette smoker. * Current use of lipid lowering medication

Design outcomes

Primary

Measure	Time frame
Incremental AUC (change from baseline in overall response) for plasma triacylglycerol concentrations	1-6 h post-meal

Secondary

Measure	Time frame
Incremental AUC for plasma non-esterified fatty acid concentrations	1-6 h post-meal
Changes from baseline in digital volume pulse	2,4,5,6 h post-meal
Changes from baseline in blood pressure	2,4,5,6 h post-meal

Other

Measure	Time frame
Incremental AUC for plasma total cholesterol concentrations	1-6 h post-meal

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026